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Abstract
Objective: To evaluate the efficacy of intra-articular (IA) glucocorticoids for knee or hip osteoarthritis  in 
specific subgroups of patients with severe pain and inflammatory signs using individual patient data 
(IPD) from existing trials.
Design: Randomized trials evaluating one or more IA glucocorticoid preparation in patients with knee or 
hip osteoarthritis , published from 1995 up to June 2012 were selected from the literature. Individual 
patient data obtained from original trials included patient and disease characteristics and outcomes 
measured. The primary outcome was pain severity at short-term follow-up (up to 4 weeks). The 
subgroup factors assessed included severe pain (≥70 points, 0 to 100 scale) and signs of inflammation 
(dichotomized in present or not) at baseline. Multilevel regression analyses were applied to estimate the
magnitude of the effects in the subgroups with the individuals nested within each study. 
Results: Seven out of 43 published randomized clinical trials (n=620) were included. Patients with severe
baseline pain had a significantly larger reduction in short-term pain, but not in mid-and long-term pain,
compared to those with less severe pain at baseline (Mean Difference 13.91; 95% 1.50 to 26.31) when
receiving IA glucocorticoid injection compared to placebo.  No statistical significant interaction effects
were found between inflammatory signs and IA  glucocorticoid injections compared to placebo and to
tidal irrigation at all follow-up points. 
Conclusions: This IPD meta-analysis demonstrates that patients with severe knee pain at baseline derive
more benefit from IA glucocorticoid injection at short term follow-up than those with less severe pain at 
baseline. 
Keywords: IPD analysis; osteoarthritis; knee; hip; IA glucocorticoid; injection
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Background
Given  the  small  to  moderate  effect  size  of  symptomatic  treatments  in  osteoarthritis  (OA)  and  the
heterogeneity of OA patients, treatment guidelines for OA have addressed the need for research on
clinical  predictors  of  response  to  these  different  treatments.[1,  2] However,  the  identification  of
responsive  subgroups  is  challenging.  In  order  to  ensure  that  the  right  patients  receive  the  right
treatment, it is essential to use appropriate methodologies. Some trials have focussed on the different
OA  joint  groups  (e.g.  hand,  hip,  knee  or  foot)  and  for  treatment  specifically  aimed  at  certain  OA
subgroups  such  as  osteotomy  for  varus  knee  OA.[3] However,  to  design  trials  on  every  available
treatment for every identified subgroup would be expensive and unrealistic. 
Post  hoc analyses within individual  trials  are frequently applied to identify subgroups with different
treatment responsiveness. However, such analyses are not powered a priori and therefore are subject
to a high risk of type I and type II errors .[4, 5] A methodologically robust method is to test for subgroup-
treatment interaction effects.[3] This method carries a much smaller risk of false-positive results but
requires large sample sizes  to detect  the interaction between subgroup variables and treatment.  A
meta-analysis  for  quantifying  interaction  effects  using  Individual  Patient  Data  (IPD)  may  help  to
overcome the power problem in individual trials.[6] In a meta-analysis using IPD, in which the data of
several  trials  are  pooled,  the  interaction effects  between subgroups and  treatment  can be  reliably
assessed and potential confounders at both study and individual patient levels can be adjusted for.[6]
The OA Trial Bank initiative was therefore commenced in 2010 to collect and analyse IPD of published
RCTS in OA.[7] The OA trial bank brings together data from individuals with OA recruited for published
RCTs from different countries around the world to form a databank. 
Intra-articular (IA) glucocorticoid injections are frequently applied in knee or hip OA patients who are
unresponsive to non-invasive treatments or oral non-steroidal anti-inflammatory drugs (NSAIDS). An IA
glucocorticosteriod  injection  is  particularly  recommended  for  OA  patients  with  signs  of  local
inflammation.[2,  8-11] The  Cochrane  systematic  review  on  the  effectiveness  of  IA  glucocorticoid
injection in knee OA found some evidence for the efficacy of IA glucocorticoid injections compared to IA
placebo for  pain  and patient  global  assessment  at  one week post  injection,  with  evidence also for
continuing efficacy at two and three weeks post-injection.[10] It is however suggested that especially
patients with clinical evidence of inflammation would benefit more from IA glucocorticoid injections.[12]
However,  Jones  et  al.  could  not  confirm  these  findings.[13] To  date,  no  IPD  analyses  have  been
performed to study interaction effects in frequently applied OA interventions. The primary aim of this
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study is to evaluate the efficacy of IA glucocorticoids for knee or hip OA in specific subgroups of patients
according to the severity of pain and inflammatory signs, over both short and long term follow-up, using
individual patient data from published trials.
Methods
We carried out an IPD meta-analysis  of  RCTs studying the efficacy of  IA glucocorticoid injections in
patients with hip or knee OA. Full study protocol details have been published.[7]
Study selection
The following inclusion criteria were applied for studies to be included in the OA trial bank for the
current study purpose:
Type of studies
All RCTs, including crossover trials, evaluating one or more IA glucocorticoid preparations in patients
with OA of the knee or hip. There were no language restrictions. 
Participants
Participants have a diagnosis of OA of the knee or hip: 
(1) according to the American College of Rheumatology (ACR) classification criteria.[14, 15]
(2) on the basis of detailed clinical and/or radiographic information.
Studies including a subgroup of knee or hip OA patients were also included. 
Types of interventions
All IA glucocorticoid preparations used for treatment of OA of the knee or hip in humans, compared to
control  treatments including: placebo,,  IA hyaluronan/hylan, other doses of IA glucocorticoids, usual
conservative  treatments,  or  compared to different  types  of  injection procedures  of  glucocorticoids.
Trials were grouped into three different comparisons: 1. IA glucocorticoid injection versus placebo; 2. IA
glucocorticoid injection versus hyaluronic acids and 3. IA glucocorticoid injection versus tidal irrigation. 
Types of baseline assessments
(1) Important confounders: as a minimum baseline severity of pain, age and gender should have been
assessed at baseline.
(2) If available:
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Signs of inflammation should have been assessed at baseline, either by physical examination
(warmth, effusion) or by additional testing (ultrasound, MRI, biopsy, serum CRP/ESR). 
Types of outcomes
The minimum criterion for inclusion was reporting of pain. The primary outcome measure was pain
severity at short-term (up to 4 weeks) follow-up. Secondary outcomes included pain severity at mid-
term (closest to 3 months) and long-term follow-up (closest to 12 months). Information regarding other
OMERACT III core set of outcome measures including physical function and patient global assessment
were analysed when feasible.[16]
Subgroup analyses
Subgroup  analyses  were  performed  for  the  primary  and  secondary  outcomes  in  the  subgroups  of
patients with and without severe pain (≥70 on 0-100 scale) and with and without inflammatory signs
(yes/no). 
Identification of eligible studies
The following databases were searched from 1995 (based on availability of data sets and authors) until 
19 June 2012 for RCTs of IA glucocorticoid versus control treatment for OA of the knee or hip: the 
Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); EMBASE, Web of Science,
Scopus, Cinahl, Pedro and the controlled trial registers. (Appendix 1) In addition, reference lists were 
hand searched for further identification of published work. Potential on-going studies were searched by 
Horizon scanning documents from Arthritis Research UK (including European Patent Office; Intellectual 
Property Office; NHS - Database of Uncertainties about the Effects of Treatments (DUETS); ISRCTN 
Registry of Clinical Trials; ClinicalTrials.gov; UKCRN Portfolio Database; Australian New Zealand Clinical 
Trials Registry; Netherlands Trials Register; German Clinical Trials Register). 
Two review authors (MM, SB) independently selected citations based on titles and abstracts. Full articles
were obtained for the citations that met the eligibility criteria and assessed by the two review authors
independently. The OA Trial Bank board members were consulted if consensus was not reached. 
Data collection and transfer
All corresponding authors of eligible trials were approached and asked for their data following the OA
Trial Bank protocol and terms.[7] All data-deliverers signed the data delivery license agreement. Data
sets  were accepted in  any kind of  format,  provided that  variables  and categories  were adequately
labelled within the data set or with a separate codebook. The original data collection files were kept in
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their original version and saved on a secured server at the Erasmus MC University Medical Center in
Rotterdam. To ensure quality, all data were checked for consistency and numbers were compared with
published papers. In case of differences, authors were contacted and discrepancies were resolved. 
Risk of Bias assessment
The methodological quality of the studies was assessed using the twelve criteria recommended by the
Cochrane Collaboration and were evaluated independently by two researchers (Appendix 2). The criteria
were scored as ‘yes’ (low risk of bias), ‘no’ (high risk of bias) or ‘unclear’. Any disagreements between
the review authors were resolved by discussion, including input from the OA Trial Bank board members.
A study with a low risk of bias was defined as fulfilling six or more of the criteria items. 
Data extraction
From the published papers, details on the interventions and comparator groups were obtained. Data
obtained from the original databases included patient characteristics (age, gender, BMI), disease specific
characteristics (ACR criteria,  radiographic information, signs of inflammation, duration of complaint),
study  characteristics  (types  of  interventions,  doses)  and  outcome  measures  measurements  (pain,
function and global perceived recovery). All randomized patients with a database record were entered
in the pooled database and all individual trials were assigned an individual random trial number. 
Data analyses
The primary outcome was pain severity  at  short-term follow-up.  If  available  we used the VAS pain
measure, otherwise the WOMAC pain score was used, followed by other Likert scores but converted
into  a  VAS  0-100  scale.  Secondary  outcomes  included  pain  severity  assessed  at  other  follow-up
durations (mid-term and long-term follow-up), physical functioning (standardized to 0 to 100 scale) and
global assessment.[16] 
The heterogeneity of trials was measured using I-square – the inconsistency among studies that cannot
be explained by chance.[17] An additional analysis was performed as appropriate by excluding the trials
causing heterogeneity in order to reach an I-square index of below 50. 
Overall effects between the different comparative treatments on the primary outcome pain at all follow-
up points were estimated using multilevel regression analyses. The analyses were adjusted for baseline
pain,  age and gender. Data were not imputed since all  trials  included had less than 15% of missing
values.
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The subgroup factors were, based on consensus, standardised to a.) severe pain, yes (≥70 points) or no
(<70  points)  and  b.)  signs  of  inflammation  (yes  or  no).  In  addition  separate  pooled  analysis  was
undertaken for the different definitions of inflammation. 
All analyses were repeated for hip and knee OA participants separately where more than one RCTs could
be included in the analyses.
Multilevel regression analyses were applied to estimate the magnitude of the effects in the different
subgroups  with  the  individuals  nested  within  each  study,  adjusted  for  age  and  gender.  To  assess
potential subgroup effects, a random-effects linear regression model was used to calculate interaction
effects. The model included the dependent variable, i.e. pain intensity at follow-up (0-100 scale) and
independent variables, i.e. treatment (glucocorticoid injection or control), the effect modifier (severe
pain (yes or no) or signs of inflammation (yes or no)), and an interaction term (pain BY treatment or
inflammation BY treatment). The interaction effects represent the combined effects of severe pain or
inflammation on pain severity and therefore represent the difference in effectiveness for the subgroup
effects of  IA  glucocorticoid  injection on pain severity.  Interaction effects were only tested for these
comparisons including more than one RCT. Interaction effect with p-value less than 0.05 was considered
as  statistically  significant,  indicating  that  the  outcome depends  on  the  severity  of  pain  or  signs  of
inflammation at baseline. For statistical significant interaction terms, separate subgroup effects were
calculated to assist the interpretation of the results. The clinical significance of the interaction effect was
estimated by the effect size (Cohen’s d - the adjusted effect estimate of the interaction term divided by
the pooled standard deviation of the baseline pain scores). An effect size of 0.2 was considered small
and 0.5 moderate, while and effect size >0.8 indicates a large clinical effect.[18] 
Results
Description of the studies
Of the 420 publications identified from the literature search, 43 publications met the eligibility criteria.
Of  these,  13  were duplicate  publications and therefore  30 publications  were eligible.  A  total  of  23
authors  were for  several  reasons unresponsive  (Figure  1).[12, 13,  19-39] Following written request,
authors of seven studies agreed to participate and were able to deliver their data to the OA Trial Bank.
These seven published RCTs included 620 patients fulfilling the eligibility criteria and were included in
the OA Trial Bank for the current study purpose.[40-46] Of these, four studies [41, 43, 45, 46] compared
glucocorticoids (n=116) with placebo (n=107), two studies [41, 44] compared glucocorticoids (n=72) with
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hyaluronic acid (n=71), two studies [40, 46] compared glucocorticoids (n=104) and tidal irrigation (n=92)
and one study [42] compared glucocorticoids with botulinum toxin injections (n=60). An overview of the
included studies is presented in Table 1. Five studies [40, 42-44, 46] included patients with knee OA only
and two [41, 45] included hip OA patients only. All studies reported on pain at both short and mid-term
follow-up, while six studies reported on function outcomes (WOMAC) and three studies reported on a
global assessment. 
Table 2 presents the baseline characteristics of the study participants for each comparison. The average
age  was  about  65  years  and  49.7%  were  women.  Severe  pain  was  present  in  34.4%  of  the  total
population,  with  the  highest  number  in  the  studies  comparing  glucocorticosteriod  injections  with
hyaluronic acids. Inflammatory signs, measured in five studies, were present in 41.8% of all subjects. 
The risk of bias scores of the individual studies are presented in Table 3. All studies scored positive on at
least  5  out  of  11  points,  with  all  studies  scoring  positive on the items ‘method of  randomization’,
‘compliance acceptable’ and ‘timing of outcome assessment’. Two studies scored negative on all three
blinding issues.[40, 41]
Overall treatment effects
A significant overall effect on the primary outcome pain severity at short-term follow-up was seen of IA
glucocorticoid injection compared to placebo (Mean Difference (MD) 18.72 (95% Confidence Interval (CI)
13.04 to24.41)) and compared to hyaluronic acid (MD 9.38 (95%CI 5.69 to13.09) (Table 4). 
At long-term follow-up there was a significant overall negative effect of IA glucocorticosteriod injection
compared to tidal irrigation (MD -4.57 (95%CI -7.40 to-1.74)). 
At  mid-term a  significant  overall  positive  effect  of  glucocorticoid injection was  found compared  to
placebo (MD 10.00 (95%CI 3.88 to 16.13) but no statistical significant differences were found at long-
term following when glucocorticoid injection was compared to placebo. 
Subgroup analyses among knee and hip OA patients separately revealed overall significant effects of IA
glucocorticoid injection compared to placebo at short-term in both patient populations; 13.93 (95%CI
6.41 to 21.46) and 24.54 (95%CI 16.28 to 32.82), respectively. At mid-term, a significant overall effect
was seen of IA glucocorticoid injection compared to placebo in hip OA patients only (13.58 (95%CI 3.53
to 23.62) but not in knee OA patients (6.90 (95%CI -0.66 to 14.47)). No significant treatment effects
were found at long-term follow-up in either the knee or hip OA subgroups (data not shown). 
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Baseline pain severity and treatment effect
A significant positive interaction (13.91; 95%CI 1.50 to 26.31) was found between severe pain at baseline
and the treatment effect of IA  glucocorticoid injection compared to placebo at short-term follow-up
(Table  5).  This  was  illustrated  by  the  statistically  significantly  larger  reduction  in  short  term  pain
(adjusted effect estimate 28.54; 95%CI 13.56 to 43.51) in patients with severe pain compared to those
with less severe pain at baseline (14.97; 95%CI 9.57 to 20.37) when receiving IA glucocorticoid injection
compared  to  placebo.  No  significant  interaction  effects  were  found  between  severe  pain  and  the
treatment effect of IA glucocorticoid injection compared to placebo at mid- and long-term follow-up. No
significant  interaction  effects  were  found  between  severe  pain  and  the  treatment  effect  of  IA
glucocorticoid injection compared to hyaluronic acid and tidal irrigation. 
Subgroup analysis  on knee OA patients also revealed a significant interaction (18.04; 95%CI 1.87 to
34.20) between severe pain and IA glucocorticoid injection compared to placebo at short-term follow-
up. This was illustrated by the statistically significantly larger reduction in short term pain (adjusted
effect estimate 27.28; 95%CI 6.72 to 47.83) in patients with severe pain compared to those with less
severe pain at baseline (9.54; 95%CI 2.65 to 16.44) when receiving IA glucocorticoid injection compared
to placebo. No significant interaction was found at mid-term follow-up (5.15; 95%CI -11.79 to 22.10). No
significant interaction effects between severe pain and IA glucocorticoid injection compared to placebo
were found in hip OA patients at any follow-up point (data not shown). 
Baseline inflammatory signs and treatment effect
No  significant  interaction  effects  were  found  between  inflammatory  signs  and  IA  glucocorticoid
injections compared to placebo and compared to tidal irrigation at all follow-up points (Table 6). 
The  interaction  effect  between  inflammatory  signs  detected  by  ultrasound  and  IA  glucocorticoid
injection compared to placebo at short-term follow-up was not statistically significant (9.04; 95%CI -0.71
to 18.80)  (Table 7). 
No significant interaction effects were found between inflammatory signs and IA glucocorticoid injection
and placebo in knee OA patients on both short-term (-3.83; 95%CI -18.98 to 11.31) and mid-term (1.49;
95%CI -13.96 to 16.94) follow-up. No analyses could be performed on hip OA patients only, since only
one study was available. 
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Discussion
The individual patient data meta-analyses on IA glucocorticoid injection showed that there is an overall
positive,  and  clinically  relevant  (>10  points  on  0-100  scale),  effect  of  IA  glucocorticoid injection
compared to placebo at short- and mid-term follow-up, with estimate reduction in pain of 18.7 and 10.0
(on a 0-100 scale) respectively. Compared to hyaluronic acid injection, an overall positive effect of IA
glucocorticoid injection  was  found  at  short-term  only.  Patients  with  severe  baseline  pain  had  a
significantly larger reduction in short term pain (adjusted effect estimate 28.54; 95%CI 13.56 to 43.51)
than  those  with  less  severe  pain  at  baseline  (14.97;  95%CI  9.57  to  20.37)  when  receiving  IA
glucocorticoid injection compared to placebo. The difference was well presented with the interaction
term between the treatment and the subgroup indicator in the multilevel regression model (Table 5).
Similar result was observed in knee OA with a slightly greater difference between severe versus less
severe knee pain at baseline (18.04; 95%CI 1.87 to 34.20). However, no firm conclusions could be drawn
on the subgroup effect  of  inflammation,  though a  positive non-significant  trend was noted for  the
effectiveness  of  IA  glucocorticoid injection  in  the  subgroup  of  patients  with  inflammatory  signs
measured by ultrasound. No statistically significant interaction effects were found in the subgroup of hip
OA patients.
IA  glucocorticosteriod  injections  are  commonly  applied  to  relieve  symptoms  of  knee  and  hip  OA;
however,  factors predicting the response to treatment are poorly understood. Maricar et al.  (2013)
aimed to determine factors associated with response to IA glucocorticosteriod injection by summarizing
the literature.[47] The authors of this review concluded that no consistent predictors of response were
identified  for  IA  glucocorticosteriod  injection  in  knee  OA.  However,  effusion,  absence  of  synovitis,
delivering injections under US guidance, structural severity of disease and pain were features that were
reported by individual studies as enhancing the response of IA glucocorticosteriod injections. [12, 13, 40,
43, 48] 
The  current  meta-analysis  aimed  to  identify  the  possible  subgroup  effects  of  severe  pain  and
inflammatory signs. In agreement with Maricar et al. (2013) we found a significant and clinically relevant
interaction  effect  (moderate  effect  with  effect  size  0.56)  between  severe  pain  at  baseline  and  IA
glucocorticosteriod injection. Severe pain was defined as a pain score higher than 70 points on a 0-100
scale.  Earlier  studies  have  indicated  that  radiographic  severity  of  knee  OA  would  be  predictive  to
response on IA glucocorticosteriod injection  [40, 49] while self-perceived symptom severity was not
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found  predictive  for  the  treatment  response  in  two  other  studies.[12,  50] The  fact  that  different
outcomes are seen between these studies and our meta-analyses could be due to the small sample size
of the individual studies and the difference in studies included. Following our protocol, we analyzed the
subgroup effect of patients with severe pain on an easy applicable measure for clinical practice. The
results  of  this  meta-analysis  indicate  that  both  patients  with  and  without  severe  pain  at  baseline
clinically  benefit from IA glucocorticosteriod injection compared to placebo at  short-term follow-up.
Although  patients  with  severe  pain  achieved  significantly  more  benefit  from  IA  glucocorticosteriod
injection compared with patients with less severe pain, with a clinically relevant difference of 14 points
on a 0 to 100 pain scale.  This  effect seems to be most predominant in knee OA patients since no
significant interaction effects were found in the small hip OA patient subgroup. However, no statistical
significant subgroup effects were found on any of the other follow-up points or between the other
comparisons.  This  is  however  consistent  to  the  overall  effect  of  IA  glucocorticosteriod  injection,
primarily showing significant effects at short-term follow-up, with the largest, and clinically relevant,
effect found at short-term follow-up, comparing IA glucocorticosteriod injection to placebo. 
OA is sometimes considered a non-inflammatory degenerative disease, however it is now recognized
that inflammation may play a role in the pathogenesis in at least some patients. IA glucocorticosteriod
injections have been used for the treatment of OA for many years and it has been suggested that these
injections are most effective in patients with evidence of inflammation on physical examination.  The
main indication for IA glucocorticoid use is to provide pain relief in patients whose condition remains
unresponsive to or intolerant of oral systemic medication.[45] However, conflicting effects have been
found in the different subgroups and most individual studies were underpowered to examine subgroup
effects in OA populations.[12, 43] In our pooled IPD meta-analysis a non-significant positive interaction
was found for the short- and mid-term treatment response on IA glucocorticosteriod injection compared
to placebo for patients with inflammatory signs, detected by ultrasound. However, by removing baseline
pain from the adjusted analyses, the positive interaction between the ultrasound inflammation and the
treatment was no longer seen. Therefore it seems that severe pain is the best and most easy measure to
predict the treatment response of IA glucocorticosteriod injections of patients with knee or hip OA. 
Strengths and limitations
The key strength of this study is that we used individual patient data from seven trials giving the study
greater power than any of the individual studies that have been conducted on potential predictors of
response for the treatment of IA  glucocorticoid injection in patients with knee or hip OA. There was
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some heterogeneity within the first comparison (see Table 4). Therefore we repeated the analyses for
both  short-and  mid-term  subgroup  effects  of  IA  glucocorticoid  injections  compared  to  placebo  by
excluding the study of Chao et al. (reduction of I2 to 0%). This did however result in comparable effect
estimates. In addition, all analyses performed were predefined and described in our published protocol.
[7] There are also several limitations. Based on the literature we approached the authors of 43 potential
eligible publications, including 13 duplicate publications. Of the 30 potentially available studies only
seven authors  agreed to participate.  As a consequence,  only two studies could be included for  the
analyses comparing IA  glucocorticoid injection with hyaluronic acid and tidal irrigation and a possible
selection bias might have occurred. This proves the challenge of collecting data of performed RCTs.
Authors of nine publications indicated that the data were no longer available and data rights of an
additional three RCTs were sold. This strengthens the rationale for the recent initiative of journals to
require authors to make trial data accessible on reasonable request. 
We included the study of Boon et al. which was not included in the subgroup analyses since this was the
only study comparing IA glucocorticoids with botulinium toxin. Since our intention was to include all
studies with non-surgical comparators, we decided to include this study in the OA Trial Bank despite that
this intervention was not pre-specified in our protocol paper.
We planned to perform subgroup analyses on both severe pain and signs of inflammation, however only
four  of  the  six  studies  included  in  the  analyses  actually  measured  signs  of  inflammation.  As  a
consequence, the subgroup effect of inflammation could not be calculated for the comparison between
IA  glucocorticoid injection  and  hyaluronic  acids  and  long-term  analysis  was  only  possible  for  the
comparison between IA glucocorticoid injection and tidal irrigation. In addition, the subgroup analyses
for inflammation are likely to be underpowered due to the low number of subjects included.  Since
inflammation was measured and reported in many different ways, it is therefore recommended that
special interest groups will reach consensus on these measures to allow meta-analyses in future.
Finally, we were forced to make some amendments on our published protocol.[7] We intended to adjust
for at least age, gender and BMI. However, since not all studies collected data to calculate the BMI, we 
were not able to adjust the analyses for BMI. 
Clinical implications
This individual patient data meta-analysis shows that patients with severe pain at baseline significantly
more benefit from IA glucocorticoid injection than those with less severe pain at short term follow-up.
However, both patients with and without severe pain show clinical relevant effects (>10 points on 0-100
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pain  scale)  of  IA  glucocorticoids  at  short-term follow-up.  No firm conclusions  can be drawn on the
additional benefit of IA glucocorticoid in the subgroup of patients with inflammatory signs due to the
limited power of the study for this subgroup. Since severe pain is easy to measure in patients in daily
practice, we suggest to use this measure to identify those patients with knee or hip OA who would
benefit the most from IA glucocorticoid injections. 
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Figure 1. Flow diagram of search and included studies 
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